Nilotinib

IUPAC Name: 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide 
Following is the structure of Nilotinib (CAS NO.641571-10-0):
                     
Empirical Formula: C₂₈H₂₂F₃N₇O
Molecular Weight: 529.5158
Index of Refraction: 1.649
Molar Refractivity: 141.75 cm³
Molar Volume: 388.6 cm³
Density: 1.36 g/cm³
Polarizability: 56.19 10^-24cm³
Surface Tension: 47.4 dyne/cm
Appearance of Nilotinib (CAS NO.641571-10-0): Off-White Solid
Product Categories: API; Molecular Targeted Antineoplastic; Nucleotides and Nucleosides; Bases & Related Reagents; Intermediates & Fine Chemicals; Nucleotides; Pharmaceuticals; Pharmaceutical intermediate
Canonical SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)
C5=CN=CC=C5
InChI: InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
InChIKey: HHZIURLSWUIHRB-UHFFFAOYSA-N
Nilotinib is a selective Bcr/Abl  tyrosine kinase inhibitor with the form of the hydrochloride monohydrate salt. Nilotinib is an analog of Imatinib with similar multiple kinase targets, but without inhibition of the Src gene.

Chemists created nilotinib with the idea of improving the target specificity of an earlier kinase inhibitor, imatinib. Novartis, the manufacturer, says Nilotinib caused a hematologic response in 74% of cases in clinical trials for use on Ph+ CML leukemia. It appears that these drugs seem to improve the action of cancer treatment in certain conditions, but actually have detrimental effects in other conditions. In October 2007, the FDA approved Nilotinib for CML. In June 2008 Italian doctors presented evidence of the efficacy and tolerability of nilotinib in CLL. The complete cytogenic response among patients in their tests was 84%.

 Nilotinib (CAS NO.641571-10-0) is used in treatment of leukemia (specifically chronic myeloid leukemia). In that study 92% of patients (already resistant or unresponsive to Gleevec) achieved a normal white blood cell counts after five months of treatment. The drug carries a black box warning for possible heart complications.

Nilotinib may cause QTc prolongation , such as an irregular heart rhythm that can LEAD to fainting, loss of consciousness, seizures, or sudden death.

 Nilotinib , its cas register number 641571-10-0. It also can be called AMN 107 ; AMN107 ; Nilotinib ; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide ; Tasigna ; and UNII-F41401512X . Its classification code are Antineoplastic and Antineoplastic Agents .